SCHEMBL23200034

SCHEMBL23200034

C#Cc1cnc(NC(=O)N(Cc2ccc(C)o2)C2CCCC2)nc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.46
▸ GAA P10253 2/20 0.42
▸ UBE2M P61081 1/20 0.41
▸ DCUN1D1 Q96GG9 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ PKM P14618 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ THRB P10828 2/20 0.39
▸ ALDH1A1 P00352 3/20 0.36
▸ TP53 P04637 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23199995 0.88 LMNA (0.44) LMNAGAAUBE2MDCUN1D1KDM4E
SCHEMBL23200130 0.85 LMNA (0.48) LMNAGAAUBE2MDCUN1D1KDM4E
SCHEMBL23699963 0.80 LMNA (0.44) LMNAGAAUBE2MDCUN1D1KDM4E
SCHEMBL23200095 0.78 LMNA (0.48) LMNAGAAUBE2MDCUN1D1KDM4E
SCHEMBL23199964 0.77 UBE2M (0.47) LMNAGAAUBE2MDCUN1D1KDM4E
SCHEMBL23200224 0.77 ALDH1A1 (0.50) LMNAGAAUBE2MDCUN1D1KDM4E
SCHEMBL23200048 0.76 ALDH1A1 (0.61) LMNAGAAUBE2MDCUN1D1KDM4E
SCHEMBL23200066 0.76 POLB (0.55) LMNAGAAUBE2MDCUN1D1KDM4E
SCHEMBL23200222 0.76 LMNA (0.51) LMNAGAAUBE2MDCUN1D1KDM4E
SCHEMBL23200025 0.75 UBE2M (0.60) LMNAGAAUBE2MDCUN1D1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3802503-A1 UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM E-Therapeutics plc (GB) 2021-04-14 — — EP claimed
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM E-THERAPEUTICS PLC (GB) 2021-08-05 — — US disclosed
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM E-THERAPEUTICS PLC (GB) 2021-08-05 — — US disclosed
EP-3802503-A1 UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM E-Therapeutics plc (GB) 2021-04-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM TPH1, KYNU, TPH2 LMNA 4541/4885GAA 1248/4885UBE2M 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback